• Publications
  • Influence
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
BACKGROUND Chronic heart failure is associated with high mortality and morbidity. Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rateExpand
  • 1,155
  • 53
  • PDF
Resting heart rate in cardiovascular disease.
The importance of resting heart rate (HR) as a prognostic factor and potential therapeutic target is not yet generally accepted. Recent large epidemiologic studies have confirmed earlier studies thatExpand
  • 818
  • 20
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.
BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with aExpand
  • 362
  • 16
  • PDF
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
Background—Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure.Expand
  • 964
  • 13
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
BACKGROUND Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated withExpand
  • 219
  • 12
Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial
Background—Heart rate reduction should benefit patients with chronic stable angina by improving myocardial perfusion and reducing myocardial oxygen demand. This study evaluated the antianginal andExpand
  • 463
  • 10
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
AIMS Heart failure (HF) has a major impact on health-related quality of life (HQoL). The aim was to evaluate whether heart rate (HR) reduction with ivabradine can translate into increased HQoL inExpand
  • 156
  • 10
Cardiovascular drug development: is it dead or just hibernating?
Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeuticExpand
  • 104
  • 10
Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure.
Clinical studies have indicated the existence of an "obesity paradox" in patients with chronic heart failure (HF), that is, reduced mortality in patients who have elevated body mass index (BMI)Expand
  • 204
  • 9
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure
OBJECTIVES This study used the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) database to assess the impact of background beta-blocker dose on response toExpand
  • 197
  • 9